Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-333824
Filing Date
2026-08-05
Accepted
2026-08-05 07:06:25
Documents
61
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q nams-20260630.htm   iXBRL 10-Q 2021584
2 EX-10.2 nams-ex10_2.htm EX-10.2 98160
3 EX-31.1 nams-ex31_1.htm EX-31.1 17540
4 EX-31.2 nams-ex31_2.htm EX-31.2 17497
5 EX-32.1 nams-ex32_1.htm EX-32.1 9855
6 EX-32.2 nams-ex32_2.htm EX-32.2 9829
  Complete submission text file 0001193125-26-333824.txt   7749691

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nams-20260630.xsd EX-101.SCH 767568
65 EXTRACTED XBRL INSTANCE DOCUMENT nams-20260630_htm.xml XML 1574650
Mailing Address GOOIMEER 2-35 NARRDEN P7 1411 DC
Business Address GOOIMEER 2-35 NARRDEN P7 1411 DC 35 206 2971
NewAmsterdam Pharma Co N.V. (Filer) CIK: 0001936258 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41562 | Film No.: 261241304
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)